176 related articles for article (PubMed ID: 33137555)
1. Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates.
Zhang B; Hu XT; Gu J; Yang YS; Duan YT; Zhu HL
Bioorg Chem; 2020 Dec; 105():104390. PubMed ID: 33137555
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors.
Zhang B; Hu XT; Zhou KM; Yang YS; Zhu HL
Bioorg Chem; 2020 Sep; 102():104096. PubMed ID: 32707279
[TBL] [Abstract][Full Text] [Related]
3. Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition.
Ghorab MM; El-Gaby MSA; Alsaid MS; Elshaier YAMM; Soliman AM; El-Senduny FF; Badria FA; Sherif AYA
Anticancer Agents Med Chem; 2017; 17(10):1411-1425. PubMed ID: 28356021
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
5. New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.
Güngör T; Ozleyen A; Yılmaz YB; Siyah P; Ay M; Durdağı S; Tumer TB
Eur J Med Chem; 2021 Oct; 221():113566. PubMed ID: 34077833
[TBL] [Abstract][Full Text] [Related]
6. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrazole Derivatives Containing Benzo Oxygen Heterocycle and Sulfonamide Moieties Selectively and Potently Inhibit COX-2: Design, Synthesis, and Anti-Colon Cancer Activity Evaluation.
Yan XQ; Wang ZC; Zhang B; Qi PF; Li GG; Zhu HL
Molecules; 2019 Apr; 24(9):. PubMed ID: 31052167
[TBL] [Abstract][Full Text] [Related]
9. Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.
Ren SZ; Wang ZC; Zhu XH; Zhu D; Li Z; Shen FQ; Duan YT; Cao H; Zhao J; Zhu HL
Bioorg Med Chem; 2018 Aug; 26(14):4264-4275. PubMed ID: 30031652
[TBL] [Abstract][Full Text] [Related]
10. Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis.
Lu XY; Wang ZC; Ren SZ; Shen FQ; Man RJ; Zhu HL
Bioorg Med Chem Lett; 2016 Aug; 26(15):3491-8. PubMed ID: 27349331
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
Lu X; Zhang H; Li X; Chen G; Li QS; Luo Y; Ruan BF; Chen XW; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(22):6827-32. PubMed ID: 22000948
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Cai H; Huang X; Xu S; Shen H; Zhang P; Huang Y; Jiang J; Sun Y; Jiang B; Wu X; Yao H; Xu J
Eur J Med Chem; 2016 Jan; 108():89-103. PubMed ID: 26638042
[TBL] [Abstract][Full Text] [Related]
13. Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.
Huang RZ; Liang GB; Huang XC; Zhang B; Zhou MM; Liao ZX; Wang HS
Eur J Med Chem; 2017 Sep; 138():979-992. PubMed ID: 28756264
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structural characterization, molecular docking study, biological activity of carbon monoxide release molecules as potent antitumor agents.
Liu HP; Liao Y; Ren MZ; Quan ZJ; Wang XC
Bioorg Chem; 2021 Feb; 107():104621. PubMed ID: 33465671
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
Chen Z; Wang ZC; Yan XQ; Wang PF; Lu XY; Chen LW; Zhu HL; Zhang HW
Bioorg Med Chem Lett; 2015 May; 25(9):1947-51. PubMed ID: 25866240
[TBL] [Abstract][Full Text] [Related]
18. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
Shen FQ; Wang ZC; Wu SY; Ren SZ; Man RJ; Wang BZ; Zhu HL
Bioorg Med Chem Lett; 2017 Aug; 27(16):3653-3660. PubMed ID: 28720504
[TBL] [Abstract][Full Text] [Related]
20. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells.
Markowicz-Piasecka M; Huttunen J; Zajda A; Sikora J; Huttunen KM
Chem Biol Interact; 2022 Jan; 352():109795. PubMed ID: 34953865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
